Skip to main content
European Commission logo print header

The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer


VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors. Most cancer therapies aim to target tumors cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment. Instead of targeting the tumor directly, VB-111 targets the tumor environment by disrupting the blood vessels that supply blood to the tumor and by recruiting the immune system into the tumor. This dual mechanism of action together with an excellent safety profile make VB-111 a game-changer. VBL is pursuing Ovarian Cancer as the first indication for VB-111. In the scope of this project, VBL will to finalize a Phase 3 potential-registration clinical trial, the OVAL study as well as execute all the necessary steps towards final regulatory approvals and commercialization



Net EU contribution
€ 2 500 000,00
8 hasatat street
7178106 Modiin

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 4 537 500,00